tbuckley/cabot-search huggingface dataset:
Information of APPLE 2017
Authors: Terry M. Therneau, Lewis R. Roberts, Hager A. Ahmed Mohammed, Ju Dong Yang, Nasra H. Giama, Jonggi Choi, Hawa M. Ali, Kristin C. Mara, William S. Harmsen, Russell H. Wiesner, Michael D. Leise, Naoshi Nishida, Satoru Hagiwara, Toshiharu Sakurai, Masatoshi Kudo, Tadaaki Arizumi, Hiroshi Ida, Yoshihiro Sakamoto, Norihiro Kokudo, Yoshikuni Kawaguchi, Keiichi Akita, Guido Torzilli, Masatoshi Kudo, Naoki Morimoto, Norio Isoda, Yoshinari Takaoka, Takuya Hirosawa, Shunji Watanabe, Toshiya Otake, Kozue Murayama, Mamiko Tsukui, Takeshi Fujieda, Natsumi Miyata, Kohei Ono, Shota Yamaguchi, Hironori Yamamoto, Masamitsu Kumon, Druckerei Stückle, Druckerei Stückle
Journal: Liver Cancer (2017)
No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia: a population-based study in Sweden
Authors: N Gunnarsson, M Höglund, L Stenke, F Sandin, M Björkholm, A Dreimane, M Lambe, B Markevärn, U Olsson-Strömberg, H Wadenvik, J Richter, A Själander
Journal: Leukemia (2017)

No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia : a population-based study in Sweden
Hypofractionated Postmastectomy Radiation Therapy Is Safe and Effective: First Results From a Prospective Phase II Trial
Authors: Atif J. Khan, Matthew M. Poppe, Sharad Goyal, Kristine E. Kokeny, Thomas Kearney, Laurie Kirstein, Deborah Toppmeyer, Dirk F. Moore, Chunxia Chen, David K. Gaffney, Bruce G. Haffty
Journal: Journal of Clinical Oncology (2017)

Purpose Conventionally fractionated postmastectomy radiation therapy (PMRT) takes approximately 5 to 6 weeks. Data supporting hypofractionated PMRT is limited. We prospectively evaluated a short course of hypofractionated PMRT, in which therapy was completed in 15 treatment days. Patients and Methods We delivered PMRT at a dose of 36.63 Gy in 11 fractions of 3.33 Gy over 11 days to the chest wall and the draining regional lymph nodes, followed by an optional mastectomy scar boost of four fractions of 3.33 Gy. Our primary end point was freedom from any grade 3 or higher toxicities. We incorporated early stopping criteria on the basis of predefined toxicity thresholds. Results We enrolled 69 women with stage II to IIIa breast cancer, of whom 67 were eligible for analysis. After a median follow-up of 32 months, there were no grade 3 toxicities. There were 29 reported grade 2 toxicities, with grade 2 skin toxicities being the most frequent (16 of 67; 24%). There were two patients with isolated ipsilateral chest wall tumor recurrences (2 of 67; crude rate, 3%). Three-year estimated local recurrence-free survival was 89.2% (95% CI, 0.748 to 0.956). The 3-year estimated distant recurrence-free survival was 90.3% (95% CI, 0.797 to 0.956). Forty-one patients had chest wall reconstructions; three had expanders removed for infection before radiation therapy. The total rate of implant loss or failure was 24% (9 of 38), and the unplanned surgical correction rate was 8% (3 of 38), for a total complication rate of 32%. Conclusion To our knowledge, our phase II prospective study offers one of the shortest courses of PMRT reported, delivered in 11 fractions to the chest wall and nodes and 15 fractions inclusive of a boost. We demonstrated low toxicity and high local control with this schedule. On the basis of our data, we have designed a cooperative group phase III prospective, randomized trial of conventional versus hypofractionated PMRT that will activate soon.
Isolated left ventricular failure is a predictor of poor outcome in patients receiving veno‐arterial extracorporeal membrane oxygenation
Authors: Corstiaan A. den Uil, Lucia S. Jewbali, Martijn J. Heeren, Alina A. Constantinescu, Nicolas M. Van Mieghem, Dinis dos Reis Miranda
Journal: European Journal of Heart Failure (2017)
Identification of a Novel ITGαvβ6-Binding Peptide Using Protein Separation and Phage Display
Authors: Annette Altmann, Max Sauter, Saskia Roesch, Walter Mier, Rolf Warta, Jürgen Debus, Gerhard Dyckhoff, Christel Herold-Mende, Uwe Haberkorn
Journal: Clinical Cancer Research (2017)

Purpose: Targeted therapies are regarded as promising approaches to increase 5-year survival rate of head and neck squamous cell carcinoma (HNSCC) patients.Experimental design: For the selection of carcinoma-specific peptides membrane proteome of HNO97 tumor cells fractionated by the ProteomeLab PF2D system and corresponding HNO97 cells were deployed for an alternating biopanning using a sunflower trypsin inhibitor1-based phage display (SFTI8Ph) library. Stability, binding properties and affinity of novel candidates were assessed in vitro using radio-HPLC, binding experiments and surface plasmon resonance assay (SPR), respectively. Subsequently, the affinity of the peptide was verified in situ by using peptide histochemistry, in vitro using flow cytometry, and in vivo by positron emissions tomography (PET/CT).Results: We identified a novel ITGαvβ6 binding peptide (SFITGv6) containing the amino acid sequence FRGDLMQL. SFITGv6 provides stability over a period of 24 hours and demonstrates high affinity (KD = 14.8 nmol/L) for ITGαvβ6 In HNO97 cells, a maximal uptake and internalization of up to 37.3% and 37.5%, respectively, was measured. Small-animal PET imaging and biodistribution studies of HNO97 xenografted Balb/c nu/nu mice showed tumor-specific accumulation of 68Ga- and 177Lu-labeled DOTA-SFITGv6, respectively, 30 to 60 minutes after injection. Moreover, peptide histochemistry revealed a strong and homogenous binding of biotin-labeled SFITGv6 to HNSCC tumors and breast- and lung cancer-derived brain metastases. Finally, first PET/CT scans of HNSCC and NSCLC patients displayed SFITGv6 accumulation specifically in tumors, but not in inflammatory lesions.Conclusions: Thus, SFITGv6 represents a novel powerful tracer for imaging and possibly for endoradiotherapy of ITGαvβ6-positive carcinoma. Clin Cancer Res; 23(15); 4170-80. ©2017 AACR.
ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia
Authors: D. Currow, J.S. Temel, A. Abernethy, J. Milanowski, J. Friend, K.C. Fearon
Journal: Annals of Oncology (2017)

Cancer anorexia-cachexia is a debilitating condition frequently observed in NSCLC patients, characterized by decreased body weight, reduced food intake, and impaired quality of life. Anamorelin, a novel selective ghrelin receptor agonist, has anabolic and appetite-enhancing activities.ROMANA 3 was a safety extension study of two phase 3, double-blind studies that assessed safety and efficacy of anamorelin in advanced NSCLC patients with cachexia. Patients with preserved Eastern Cooperative Oncology Group ≤2 after completing 12 weeks (w) on the ROMANA 1 or ROMANA 2 trials (0-12 weeks) could enroll in ROMANA 3 and continue to receive anamorelin 100 mg or placebo once daily for an additional 12w (12-24 weeks). The primary endpoint of ROMANA 3 was anamorelin safety/tolerability (12-24 weeks). Secondary endpoints included changes in body weight, handgrip strength (HGS), and symptom burden (0-24 weeks).Of the 703 patients who completed ROMANA 1 and ROMANA 2, 513 patients entered ROMANA 3 (anamorelin, N = 345, mean age 62.0 years; placebo, N = 168; mean age 62.2 years). During ROMANA 3, anamorelin and placebo groups had similar incidences of treatment-emergent adverse events (TEAEs; 52.2% versus 55.7%), grade ≥3 TEAEs (22.4% versus 21.6%), and serious TEAEs (12.8% versus 12.6%). There were 36 (10.5%) and 23 (13.8%) deaths in the anamorelin and placebo groups, respectively; none were drug-related. Improvements in body weight and anorexia-cachexia symptoms observed in the original trials were consistently maintained over 12-24 weeks. Anamorelin, versus placebo, significantly increased body weight from baseline of original trials at all time points (P < 0.0001) and improved anorexia-cachexia symptoms at weeks 3, 6, 9, 12, and 16 (P < 0.05). No significant improvement in HGS was seen in either group.During the 12-24 weeks ROMANA 3 trial, anamorelin continued to be well tolerated. Over the entire 0-24w treatment period, body weight and symptom burden were improved with anamorelin.ROMANA 1 (NCT01387269), ROMANA 2 (NCT01387282), and ROMANA 3 (NCT01395914).
Strategies for Addressing a Broader Definition of Conflicts of Interest
Authors: Ross E. McKinney, Heather H. Pierce
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Discovery and Preclinical Development of Novel CD74-Targeting Antibody-Drug Conjugates (ADCs) with Significant Activity in Multiple Myeloma (MM) Cell Lines and Xenograft Models
Authors: Cristina Abrahams, Xiaofan Li, Abigail Yu, Stellanie Krimm, Jason Kahana, Rama Krishna Narla, Eric Schwartz, John Boylan, Heidi Hoffmann, Alexander Steiner, James Zawada, Heather Stephenson, Maureen Bruhns, Venita DeAlmeida, Shannon Matheny, Stuart Bussell, Adam Galan, Toni Kline, Nicki Vasquez, Alice Yam, Ryan Stafford, Henry Heinsohn, Aaron Sato, Arturo Molina, Trevor Hallam, Mark Lupher
Journal: Blood (2016)
Chronic purulent nasal discharge
Authors: Zhenxiao Huang, Jingying Ma
Journal: BMJ (2017)

A 49 year old woman was referred to a community hospital after experiencing persistent purulent nasal discharge for three years. She had not responded to antibiotics. Subsequently, she was referred to a department of otolaryngology for surgical intervention. She underwent a non-contrast computed tomography (CT) scan of her sinuses (fig 1⇓). Based on the CT scan, what is the diagnosis?



Fig 1  Coronal computed tomography (CT) scan of the sinus



A fungal ball, also known as a mycetoma, in the right nasal cavity.

### Discussion

The coronal sinus CT scan shows a fungal ball in the right nasal cavity …
Bronchoscopic Techniques Used in the Diagnosis and Staging of Lung Cancer
Authors: Andrew D. Lerner, David Feller-Kopman
Journal: Journal of the National Comprehensive Cancer Network (2017)

With the greater use of chest CT, the incidental detection of lung nodules is expected to increase. However, because most lung nodules are benign, there is a high demand for minimally invasive procedures that provide valuable diagnostic information while minimizing complications. Recent advances in bronchoscopic technology meet this demand. These advanced technologies include navigational bronchoscopy and radial endobronchial ultrasound (EBUS) for the diagnosis of peripheral lung nodules, and linear EBUS, which has revolutionized the nonoperative nodal staging of lung cancer and provides a complementary option to surgical staging approaches. This article reviews these new bronchoscopic technologies.
mRNA-mediated glycoengineering ameliorates deficient homing of human stem cell–derived hematopoietic progenitors
Authors: Jungmin Lee, Brad Dykstra, Joel A. Spencer, Laurie L. Kenney, Dale L. Greiner, Leonard D. Shultz, Michael A. Brehm, Charles P. Lin, Robert Sackstein, Derrick J. Rossi
Journal: Journal of Clinical Investigation (2017)

Generation of functional hematopoietic stem and progenitor cells (HSPCs) from human pluripotent stem cells (PSCs) has been a long-sought-after goal for use in hematopoietic cell production, disease modeling, and eventually transplantation medicine. Homing of HSPCs from bloodstream to bone marrow (BM) is an important aspect of HSPC biology that has remained unaddressed in efforts to derive functional HSPCs from human PSCs. We have therefore examined the BM homing properties of human induced pluripotent stem cell-derived HSPCs (hiPS-HSPCs). We found that they express molecular effectors of BM extravasation, such as the chemokine receptor CXCR4 and the integrin dimer VLA-4, but lack expression of E-selectin ligands that program HSPC trafficking to BM. To overcome this deficiency, we expressed human fucosyltransferase 6 using modified mRNA. Expression of fucosyltransferase 6 resulted in marked increases in levels of cell surface E-selectin ligands. The glycoengineered cells exhibited enhanced tethering and rolling interactions on E-selectin-bearing endothelium under flow conditions in vitro as well as increased BM trafficking and extravasation when transplanted into mice. However, glycoengineered hiPS-HSPCs did not engraft long-term, indicating that additional functional deficiencies exist in these cells. Our results suggest that strategies toward increasing E-selectin ligand expression could be applicable as part of a multifaceted approach to optimize the production of HSPCs from human PSCs.
A Mixed Type 1 and Type 2 Kinase Inhibitor That Overrides FLT3 F691 and D835 Resistance Mutations
Authors: Jack Lin, Ying Zhang, Bernice Matusow, Adam Mumy, Garson Tsang, Jiazhong Zhang, Hannah Powers, Wayne Spevak, Paul Severson, James Tsai, Gideon Bollag, Chao Zhang
Journal: Blood (2016)
Prognostic impact of complete removal of the tumor-bearing portal territory of the liver for hepatocellular carcinoma.
Authors: Junichi Shindoh, Masatoshi Makuuchi, Yutaka Matsuyama, Yoshihiro Mise, Junichi Arita, Yoshihiro Sakamoto, Kiyoshi Hasegawa, Norihiro Kokudo
Journal: Journal of Clinical Oncology (2015)

e15162 Background: Anatomic resection (AR) of the tumor-bearing portal territory has reportedly been associated with decreased recurrence of hepatocellular carcinoma (HCC). However, its oncological advantage remains controversial. This study sought to determine the local tumor control ability and prognostic advantage of AR for primary HCC based on the data from a large prospective cohort. Methods: In Child-Pugh class A patients with primary, solitary HCC measuring ≤ 5.0 cm in diameter, the clinical outcomes were compared between patients in whom complete AR was achieved and those who eventually ended up with non-anatomic limited resection of the liver (non-AR). Recurrence-free survival rates (RFS) and disease-specific survival rate (DSS) were estimated by the Kaplan-Meier method and compared by a log-rank test between AR and non-AR groups. Factors associated with local tumor recurrence and DSS were analyzed by multivariate logistic regression and Cox-proportional hazards model, respectively. Reproducibility of these results was also confirmed by adjusting the propensity score to be performed AR by the stabilized inverse probability of treatment weighting (IPTW) method. Results: Of the 209 eligible patients, 156 patients underwent complete AR and 53 patients ended up with non-AR. With median follow-up period of 93.0 months for AR group and 87.9 months for non-AR group, clear prognostic advantage of AR was observed in terms of both RFS (5-year RFS, 46.4% vs. 25.9%; P = 0.004) and DSS (5-year DSS, 83.3% vs. 65.8%; P = 0.04). The local tumor recurrence was significantly infrequent in the AR group (4.5% vs. 34.0%, P < 0.001). Multivariate analysis revealed that AR was associated with a decreased risk of local recurrence (Odds ratio [OR] 0.09, 95% CI 0.03-0.23; P < 0.001) and improved DSS (Hazard ratio [HR] 0.28, 95% CI 0.15-0.53; P < .001). These results remained unchanged even after adjustment for the propensity score (OR 0.09, 95% CI 0.03-0.24; P < 0.001 for local tumor recurrence and HR 0.38, 95% CI 0.19-0.75; P = 0.005 for DSS, respectively). Conclusions: Complete removal of the tumor-bearing portal territory decreases the risk of local tumor recurrence and improves the survival in patients with primary HCC.
Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease
Authors: Joshua J. Neumiller, Radica Z. Alicic, Katherine R. Tuttle
Journal: Journal of the American Society of Nephrology (2017)

Diabetic kidney disease is among the most frequent complications of diabetes, with approximately 50% of patients with ESRD attributed to diabetes in developed countries. Although intensive glycemic management has been shown to delay the onset and progression of increased urinary albumin excretion and reduced GFR in patients with diabetes, conservative dose selection and adjustment of antihyperglycemic medications are necessary to balance glycemic control with safety. A growing body of literature is providing valuable insight into the cardiovascular and renal safety and efficacy of newer antihyperglycemic medications in the dipeptidyl peptidase-4 inhibitor, glucagon-like peptide-1 receptor agonist, and sodium-glucose cotransporter 2 inhibitor classes of medications. Ongoing studies will continue to inform future use of these agents in patients with diabetic kidney disease.
Critical Roles of Retinoic Acid Signaling in Combating Acute Graft Versus Host Disease
Authors: Govindarajan Thangavelu, Asim Saha, Kazutoshi Aoyama, Cameron McDonald-Hyman, Yu-Chi Lee, Chrysothemis Brown, Angela Panoskaltsis-Mortari, Mark J. Osborn, Roshantha A Chandraratna, Randolph Noelle, Bruce R. Blazar
Journal: Blood (2016)
Hypertriglyceridemia and Pancreatitis—New Evidence That Less Is More—Reply
Authors: Simon B. Pedersen, Anne Langsted, Børge G. Nordestgaard
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Ranolazine After Incomplete Percutaneous Coronary Revascularization in Patients With Versus Without Diabetes Mellitus
Authors: Alexander C. Fanaroff, Stefan K. James, Giora Weisz, Kristi Prather, Kevin J. Anstrom, Daniel B. Mark, Ori Ben-Yehuda, Karen P. Alexander, Gregg W. Stone, E. Magnus Ohman
Journal: Journal of the American College of Cardiology (2017)
PPARδ Promotes Running Endurance by Preserving Glucose
Authors: Weiwei Fan, Wanda Waizenegger, Chun Shi Lin, Vincenzo Sorrentino, Ming-Xiao He, Christopher E. Wall, Hao Li, Christopher Liddle, Ruth T. Yu, Annette R. Atkins, Johan Auwerx, Michael Downes, Ronald M. Evans
Journal: Cell Metabolism (2017)
Incidental Prostate-Specific Membrane Antigen Uptake in a Peripheral Nerve Sheath Tumor
Authors: Shankar Vamadevan, Ken Le, Lily Shen, Leo Ha, Robert Mansberg
Journal: Clinical Nuclear Medicine (2017)

A 66-year-old man with recently diagnosed prostate cancer (Gleason score 9) was referred for 68Ga–prostate-specific membrane antigen (PSMA) PET/CT with prostate-specific antigen level of 7.5 μg/L. PET/CT demonstrated increased PSMA uptake (SUVmax 4.7) in a soft tissue density in the left adductor compartment. MRI and cytopathology of the biopsied soft tissue density was compatible with a peripheral nerve sheath tumor. This case illustrates that PSMA uptake can occur in a peripheral nerve sheath tumor and should be taken into consideration as a benign cause of PSMA uptake.
Rapid Detection of Avian Influenza Virus by Fluorescent Diagnostic Assay using an Epitope-Derived Peptide
Authors: Duong Tuan Bao, Do Thi Hoang Kim, Hyun Park, Bui Thi Cuc, Nguyen Minh Ngoc, Nguyen Thi Phuong Linh, Nguyen Chien Huu, Trinh Thi Thuy Tien, Nguyen Thi Viet Anh, Tung Dao Duy, Chom-Kyu Chong, Seung-Taek Yu, Do-Young Choi, Seon-Ju Yeo
Journal: Theranostics (2017)

Currently, the point of care testing (POCT) is not fully developed for subtype-specific avian influenza virus detection. In this study, an H5N1 hemaglutinin 1 (HA1) epitope (P0: KPNDAINF) and three modified peptides (P1: KPNTAINF, P2: KPNGAINF, P3: KPNDAINDAINF) were evaluated as POCT elements for rapid detection of avian influenza virus. Based on modeling predictions by Autodock Vina, binding affinity varied depending on alteration of one amino acid in these peptides. The binding energy of P2 indicated its potential for a strong interaction with HA. Fluorescence-linked immunosorbent assay experimentally demonstrated the interaction between these peptides and virus. The four peptides interacted with HA1 of H5N3 with different binding affinities with P2 showing the strongest binding affinity. When P0 and P2 peptides were used in rapid fluorescent immunochromatographic test (FICT) as detection elements, the inter-assay coefficients of variation (CV) indicated that P2-linked FICT was more acceptable than the P0-linked FICT in the presence of human specimens. Antibody pair-linked FICT was influenced by clinical samples more than the P2-linked FICT assay, which showed a 4-fold improvement in the detection limit of H5N3 and maintained H5 subtype-specificity. Compared to the rapid diagnostic test (RDT) which is not specific for influenza subtypes, P2-linked FICT could increase virus detection. In conclusion, results of this study suggest that HA epitope-derived peptides can be used as alternatives to antibodies for a rapid fluorescent diagnostic assay to detect avian influenza virus.